Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
about
Targeting Cancer Metabolism - Revisiting the Warburg EffectsMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyCIViC databaseThe AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.Therapeutic targeting of cancers with loss of PTEN function.Maximising the potential of AKT inhibitors as anti-cancer treatmentsAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitorTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092PI3K and cancer: lessons, challenges and opportunitiesA phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.Genetically engineered mouse models of PI3K signaling in breast cancer.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.A kinase-independent function of AKT promotes cancer cell survival.The Warburg effect: evolving interpretations of an established conceptCritical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Ischemic Preconditioning Mediates Neuroprotection against Ischemia in Mouse Hippocampal CA1 Neurons by Inducing Autophagy.The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentProlactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential TherapyThe RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.Targeting Akt3 signaling in triple-negative breast cancer.Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression.Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.AKT/PKB Signaling: Navigating the Network.Regulators of Glucose Metabolism in CD4(+) and CD8(+) T Cells.Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells.
P2860
Q26738876-095A7546-B860-4910-8942-44658EED3943Q26798420-810A82B7-4F0C-4B91-898F-5D71D4EA99D1Q27612411-188C903A-05A1-46B4-B362-BD5FF2166AF3Q27852562-93E05357-A86E-4406-91F2-D3D7F2955B87Q27852764-F5F43AA2-F925-4C8B-9434-48E49E9CA040Q28072254-E044FE01-8DA4-48DC-84BD-E6856AE72464Q28080599-70BCF113-8735-413B-BD7C-61D01BEC097CQ28540161-039BF9B3-202D-4A14-B5D4-0118894C86D5Q28550300-CED05781-7569-4682-A0D4-A9C25A79082DQ30080017-82965A25-5633-4AAC-88E7-398E036E0DE7Q33764664-0DD43B1E-4FFD-4089-9D6D-F47137A66564Q33874621-1180DC36-BD5D-429E-AA4B-6D62569644B0Q34332175-0AB70724-CD2C-48F8-B4A1-022B9EED426CQ34978420-CE01F7A3-55AE-462A-BC88-67CB9897A26EQ35111288-76E716CA-D835-4598-AC64-37891CDA3376Q35169587-B8A89C31-E0E0-41E3-A4A6-1F6F3229AB25Q35574950-1C3BA1E1-F534-4481-8228-597CD0A0FFB3Q35760830-F50EBB2F-D604-4E1C-8413-BE85D3DB244BQ35930433-7D5C3320-7606-4912-A632-867E872BC5FFQ36101969-26B7DD2F-8817-499D-8A59-9497AE556436Q36640327-A20C8862-DAC2-4F54-84F0-09900D45A9B0Q36997524-0B368F4D-EBDC-4FD6-A58E-C9CF2209A830Q37144576-84D7CECB-8448-4B81-9F1B-67866144A5DBQ37618018-760D8B8E-DA47-4CFA-A657-BB6C0EC1B88AQ37624534-96397698-4CA0-4C37-9882-58B39A854D6DQ37680256-68EF16E3-1756-44B3-96BB-A9FF1F300501Q38148747-192E826C-3A4C-4B9A-B048-509BC09BAD86Q38183283-DEA8CBE5-12E7-4053-84B0-9CF38688ED92Q38221107-0A7A48FD-1D8C-4C52-9E42-8082D2C7BB38Q38259259-7A7AE92B-4998-4448-976B-3858FD5E58B4Q38390966-FED9D77F-5D2B-4608-B411-15CA65787046Q38527936-A65B3F28-800A-4075-9700-F8596415AAB1Q38739375-AF4DF133-0029-4E83-AF11-CAEF82E8B010Q38740114-B338181A-76A1-472F-A69B-15CEF1925183Q38764654-1CB97473-3CD2-423F-A91B-96F1BED009E9Q38862047-E6CDC0B4-18F3-466D-BFC5-72D67A1F3CF7Q39015140-06B50E99-5162-46BE-8E5D-C92E9B6E7551Q39255027-D73ED024-A61B-4BA3-AC7F-8DDF9FFE6692Q40895626-0D7030DA-3F0E-45F1-8ED0-39E92841145BQ42362435-5CD00E16-692B-4B51-9758-5740F95AA86D
P2860
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting activated Akt with G ...... ious in multiple tumor models.
@ast
Targeting activated Akt with G ...... ious in multiple tumor models.
@en
Targeting activated Akt with G ...... ious in multiple tumor models.
@nl
type
label
Targeting activated Akt with G ...... ious in multiple tumor models.
@ast
Targeting activated Akt with G ...... ious in multiple tumor models.
@en
Targeting activated Akt with G ...... ious in multiple tumor models.
@nl
prefLabel
Targeting activated Akt with G ...... ious in multiple tumor models.
@ast
Targeting activated Akt with G ...... ious in multiple tumor models.
@en
Targeting activated Akt with G ...... ious in multiple tumor models.
@nl
P2093
P3181
P1476
Targeting activated Akt with G ...... ious in multiple tumor models.
@en
P2093
Bianca M Liederer
Brian B Lee
Deepak Sampath
Elizabeth Punnoose
Hartmut Koeppen
Heidi Savage
Jeffrey J Wallin
P304
P3181
P356
10.1158/1078-0432.CCR-12-3072
P407
P577
2013-04-01T00:00:00Z